BD launches a new generation of disposable auto-injectors

06:43 EST 8 Nov 2011 | BioPortfolio

BD Physioject™ provides an innovative solution with proven* patient acceptance, ease of use and robust system functionality

Location (08 November 2011) – BD Medical, a segment of BD (Becton, Dickinson and Company), announced today the launch of the BD Physioject™ disposable auto-injector.  This clinically proven,* reliable and cost-effective system is specifically designed for self-injection of drugs by patients suffering from chronic diseases, including rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis.

The BD Physioject™ auto-injector presents key benefits for patients such as ease of use and intuitiveness, one-button activation, 360° view of the drug and injection process, visual confirmation of the end of injection, and protection of the needle after injection.  The optimised design for delivery of subcutaneous injections is defined by patient studies to incorporate those ergonometric features most relevant to self-injection needs.  

Claude Dartiguelongue, President, BD Medical – Pharmaceutical Systems, says: “BD is committed to providing high-quality, innovative, highly customisable, cost-effective devices designed specifically to meet chronic disease patients’ needs for safety, comfort and convenience.  With BD Physioject™, developed through a robust, patient-centric design process, we aim to improve drug efficacy, the patient experience and treatment compliance.”  Clinical trials show that BD Physioject™ provides safety, efficiency, acceptance by patients, and improved pain perception versus the same syringe used by a nurse*.

BD Physioject™ can be customised to offer a modified external design, flexible injection duration, a range of possible subcutaneous injection depths, and various syringe options (such as an end-of-dose indicator) for the unique requirements of pharmaceutical and biotechnology customers.  BD Physioject™ also includes a straightforward two-part assembly process that simplifies production and manufacturing.  To further support its global customers, BD offers deep understanding and expertise of drug and device combinations through all stages of the development process, from design through to launch, including global regulatory support. 

BD Physioject™ is designed for use in combination with the BD Hypak™ for Biotech syringe, a state-of-the-art primary container optimised for use with biologics to provide, among other benefits, a low level of interaction with such drugs.  The complete integrated system offers a high-quality, reliable solution for the self-injection market. 

“We are excited to be introducing a new generation of disposable auto-injectors with the launch of BD Physioject™ and we look forward to collaborating with pharmaceutical and biotechnology companies to facilitate the development and launch of self-injection devices, with the common end goal of improving the lives of patients managing chronic diseases,” Ms. Dartiguelongue adds.

Merck Serono selected Physioject as the platform for RebiDose™, the Rebif® pre-filled pen, for the treatment of multiple sclerosis. Merck Serono announced the approval of RebiDose™ in Europe and Australia in October 2010.


About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit

Vikki Lomas
BD Corporate Communications
01865 781607

Recieved from:

Emma Warren
Lindsell Marketing, 7 Praed Street, London W2 1NJ, Tel: +44 (0)207 402 0510


More From BioPortfolio on "BD launches a new generation of disposable auto-injectors"

Quick Search